Clinical Trial: Evaluation of the Effect of Time of Administration on the Activity on First Line of Pembrolizumab in Association With Carboplatin-pemetrexed in Metastatic Non-squamous Lung Cancer. A Randomised Multicenter Phase III Trial

U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07915037) titled 'Evaluation of the Effect of Time of Administration on the Activity on First Line of Pembrolizumab in Association With Carboplatin-pemetrexed in Metastatic Non-squamous Lung Cancer. A Randomised Multicenter Phase III Trial' on Oct. 16.

Brief Summary: IMMUNOTIME is a French multicenter randomised phase III trial in patients with metastatic non-squamous non-small cell lung cancer starting first-line treatment with pembrolizumab, carboplatin and pemetrexed. Patients receive the standard regimen and are randomised to start their pembrolizumab infusions either in the morning (08:00-12:00) or in the afternoon (13:00-17:00). The trial aims t...